Mucinex dm and Conjunctivitis aggravated - a phase IV clinical study of FDA data

Summary:

Conjunctivitis aggravated is reported only by a few people who take Mucinex Dm.

The phase IV clinical study analyzes which people take Mucinex dm and have Conjunctivitis aggravated. It is created by eHealthMe based on reports of 1,973 people who have side effects while taking Mucinex dm from the FDA, and is updated regularly.

With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.



On May, 20, 2022

1,973 people reported to have side effects when taking Mucinex dm.
Among them, 3 people (0.15%) have Conjunctivitis aggravated.


What is Mucinex dm?

Mucinex dm has active ingredients of dextromethorphan hydrobromide; guaifenesin. It is often used in cough. eHealthMe is studying from 2,649 Mucinex dm users for its effectiveness, alternative drugs and more.

What is Conjunctivitis aggravated?

Conjunctivitis aggravated (worse infection of conjunctiva) is found to be associated with 658 drugs and 221 conditions by eHealthMe.

Number of Mucinex dm and Conjunctivitis aggravated reports submitted per year:

Could Mucinex dm cause Conjunctivitis aggravated?

Gender of people who have Conjunctivitis aggravated when taking Mucinex dm *:

  • female: 100 %
  • male: 0.0 %

Age of people who have Conjunctivitis aggravated when taking Mucinex dm *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 50 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 50 %
  • 60+: 0.0 %

Common drugs people take besides Mucinex dm *:

  1. Xgeva: 1 person, 33.33%
  2. Trulance: 1 person, 33.33%
  3. Revlimid: 1 person, 33.33%
  4. Questran: 1 person, 33.33%
  5. Ondansetron: 1 person, 33.33%
  6. Omeprazole And Sodium Bicarbonate: 1 person, 33.33%
  7. Norvasc: 1 person, 33.33%
  8. Nexium: 1 person, 33.33%
  9. Lotemax: 1 person, 33.33%
  10. Lopressor: 1 person, 33.33%

Common side effects people have besides Conjunctivitis aggravated *:

  1. Malaise (a feeling of general discomfort or uneasiness): 1 person, 33.33%

Common conditions people have *:

  1. Osteoporosis (bones weak and more likely to break): 1 person, 33.33%
  2. Multiple Myeloma (cancer of the plasma cells): 1 person, 33.33%

* Approximation only. Some reports may have incomplete information.

Do you take Mucinex dm and have Conjunctivitis aggravated?

Check whether Conjunctivitis aggravated is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of Mucinex dm:

Conjunctivitis aggravated treatments and more:

COVID vaccines that are related to Conjunctivitis aggravated:

How severe was Conjunctivitis aggravated and when was it recovered:

Expand to all the drugs that have ingredients of dextromethorphan hydrobromide; guaifenesin:

Common drugs associated with Conjunctivitis aggravated:

All the drugs that are associated with Conjunctivitis aggravated:

Common conditions associated with Conjunctivitis aggravated:

All the conditions that are associated with Conjunctivitis aggravated:

How the study uses the data?

The study uses data from the FDA. It is based on dextromethorphan hydrobromide; guaifenesin (the active ingredients of Mucinex dm) and Mucinex dm (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: